Clinical Trial Update: Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Mylotarg in combination with cytarabine in untreated patients over 60 with acute myeloid leukemia and high-risk myelodysplastic syndrom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED